Info Centre Home | Contents | Search | eMJA Home


4   Managing depression in a community setting

Philip B Mitchell

There are a range of effective treatments for depression that general practitioners can consider

 

Short course

 

PDF format

Synopsis - Introduction - The nature of depression in general practice - Are treatments for depression effective in the community setting? - Antidepressant medications - Psychological treatments - Recommendations for treatment - Acute management of depression - Continuation of therapy - Maintenance therapy - When to refer - Antidepressants - Psychological treatments - Conclusion - References - Authors' details - Box 1: DSM-IV criteria for major depression - Box 2: Antidepressants marketed in Australia since 1990 - dosages and adverse effects - Box 3: New antidepressants - important interactions - Box 4: Psychological therapies - Case history 1: Depression presenting as anxiety and insomnia - Case history 2: A professional woman with depression - Short course - Contents list


Synopsis
 
  • Patients with depression may be hopeless of recovery, but effective treatments are available.
  • The diagnosis of major depression indicates a strong likelihood of response to antidepressants and/or psychological treatment.
  • Patients with moderate to severe major depression benefit from antidepressant medications.
  • Most patients do best with a combination of antidepressant medications and some form of psychological therapy.
  • Psychological treatments alone are most useful with mild to moderate levels of depression.
  • It is necessary to trial an antidepressant for at least four to six weeks before changing to a different treatment.
  • Patients who respond to acute treatment should have that continued for at least four to nine months at the same dose.
  • Long-term treatment should be considered for those with recurrent depression, particularly if it is severe.

Introduction
  At least 15% of the population will suffer from significant depression at some stage of life, and at any one time about 3%-5% will have significant symptoms. In general practice, 5% of patients have major depression and another 5% have a less severe form of this illness. The depression seen in general practice often coexists with physical disorder, or may present with physical rather than psychological complaints.

The disability caused by depression has been underestimated by the medical profession; it has a pervasive effect on physical function, bodily pain, general health, family, work and social relationships, as well as mental health.


The nature of depression in general practice

 

Case history 1:
Depression presenting as anxiety and insomnia

Depressed patients experience more impairment in quality of life than patients with common medical disorders.1 They are also higher consumers of general health care.2 This stems from greater use of general medical services rather than higher mental health treatment costs (US$2390 per year as against US$1397 for patients with common medical disorders).3

General practice patients with depression usually have shorter episodes of depression and meet fewer diagnostic criteria for major depression than those seen in psychiatric clinics.4 Severity is the best predictor of the persistence of depressive symptoms (the more severe the depression, the more likely it is to persist).5,6

Tricyclic antidepressants (TCAs) are the most commonly prescribed antidepressant in general practice, and are usually prescribed at too low a dose:7 80%-90% of prescriptions are less than 125-150 mg daily,8 below recommended guidelines for management of depression in general practice.9 In one study, 52% of the general practitioners used lower than recommended daily treatment doses (as against 17% of psychiatrists) and 40% of the general practitioners as against 7% of psychiatrists prescribed for less than the recommended minimum continuation period.10


Are treatments for depression effective in the community setting?
  Most studies have been undertaken in psychiatric outpatient practice, with findings being extrapolated to general practice.

Antidepressant medications There is no doubt about the effectiveness of antidepressants in outpatient psychiatric practice. A comprehensive meta-analysis of both inpatient and outpatient controlled trials has demonstrated response rates of 50% to 55%, compared with a 30% response rate to placebo treatment.11

A trial of amitriptyline12 in general practice found it superior to placebo in patients with major depression, but not in those with minor levels of depression. This study was important in demonstrating that TCAs are of benefit in relatively mild levels of depression, but not in the mildest range. Patients with Hamilton Depression Rating Scale scores of 12 or less were just as likely to respond to the placebo treatment. (The clinician-rated Hamilton scale13 is a widely accepted index of the severity of depression. Scores of 17 or more indicate a significant degree of depression; 7-12 indicates mild depression; and less than 7 is within the normal population range.)

Psychological treatments The major study of psychological treatments in depression in general practice is that of Elkin et al., who compared imipramine plus good clinical care with cognitive therapy, interpersonal therapy and good clinical care plus placebo.14 In patients with Hamilton scores of less than 20 (moderately severe depression) there were no differences between any of these treatments, whereas in patients with more severe scores interpersonal therapy was more effective than placebo, although cognitive therapy was not. However, other studies have shown cognitive therapy to be more effective than placebo and of similar efficacy to antidepressants in outpatient depression.15,16 More recently, Mynors-Wallis et al. found that problem solving was as effective as amitriptyline, and more effective than placebo.17

Recommendations for treatment
Case history 2:
A professional woman with depression
The outcome of a consensus conference of members of the Royal College of General Practitioners and the Royal College of Psychiatrists was published in 1992,8 and a year later the Agency for Health Care Policy and Research (AHCPR) of the US Department of Health and Human Services published the Clinical practice guideline on depression in primary care.11 Both guidelines are now regarded as important benchmarks, although there has been some criticism, particularly with regard to their strong emphasis on antidepressant drugs and correspondingly less stress on the role of psychological treatments, particularly for the mildly depressed.18,19 The major Australian guidelines are in the Psychotropic drug guidelines.20 Clinical practice guidelines for managing depression in young people have recently been published by the National Health and Medical Research Council.21,22

Acute management of depression

 

Box 1:
DSM-IV criteria for major depression

Which forms of depression are likely to respond to treatment?
The diagnosis of major depression (Box 1) -- with or without melancholic features -- indicates a strong likelihood of response to antidepressants or psychological treatment. In less severe forms of depression, either long-lasting (dysthymic disorder) or more acute (adjustment disorder with depressed mood), response to treatment is less predictable. None the less, some patients with dysthymic disorder and adjustment disorder do respond to antidepressant therapies.

Most patients with major depression in general practice do not have melancholic or endogenous features (i.e., pervasive anhedonia, psychomotor retardation or agitation, or reduced emotional reactivity). Patients with bipolar disorder (manic-depressive illness) must be identified by questioning about possible past episodes of hypomania or mania, as such patients will require a mood stabiliser (e.g., lithium, carbamazepine or sodium valproate) in conjunction with the chosen antidepressant therapy. Similarly, patients with psychotic depression (those with delusions and/or hallucinations) must be identified, as they will require treatment with electroconvulsive therapy (ECT) or a combination of antidepressants and antipsychotics.

Many depressed patients seen in general practice also have a physical disorder, and the depression is often caused by their disability, discomfort or distress. This does not preclude the effectiveness of medications or psychological treatments. Rarely, depression may be due directly to the physical condition (for example, with some endocrinopathies or cerebrovascular disease) or the drugs used to treat the disorder (e.g., corticosteroids or treatments for Parkinson's disease).

When should antidepressant medications be used?
Most patients with major depression -- particularly those with moderate to severe levels, or melancholic features -- will benefit from antidepressant medications. However, research such as that of Paykel et al.12 indicates that antidepressants are more effective than placebo even in those with relatively mild depression.

Factors that may suggest the use of antidepressants include incomplete response to psychotherapy alone, a patient request for antidepressants, chronic symptoms (two years or more), previous episodes of depression, a family history of depression, and previous response to antidepressants.11

Combined antidepressant medication and psychological treatments
Most patients do best with a combination of antidepressant medications and some form of psychological therapy. The need for combined medication and psychological treatments may be indicated by an incomplete response to antidepressants or psychological treatments alone or a poor recovery from symptoms between episodes of depression.

When to use psychological treatments alone
Such treatments are probably most useful for those with mild to moderate levels of depression. Other features that would suggest this choice of therapy include chronic psychosocial problems, a previous positive response to psychological treatments, failure to respond to antidepressant medications, and patient preference.

What is an adequate course of treatment?
Recommendations vary; for example, the AHCPR guidelines11 recommend continuing medication for six weeks before considering another treatment. The study of Nierenberg et al. of response to treatment with fluoxetine found that 36% of patients with no improvement at two weeks finally responded to treatment at eight weeks.24 The response rates at eight weeks in patients with no improvement at four and six weeks were 19% and 7%, respectively. In view of these results, a four- to six-week trial of an antidepressant is reasonable before trying a drug from another class.

Unfortunately, there are no studies to indicate how long a course of psychological treatment should be continued before such treatment is changed.

Continuation of therapy Patients who respond to acute treatment should continue therapy with the same dose of antidepressant for four to nine months to prevent a relapse of the original episode.25

Maintenance therapy Studies have confirmed the value of ongoing medications in preventing recurrences of depression.26 Maintenance therapy should be considered for those who have had three previous episodes of depression, those with two previous episodes if such episodes were recent and severe, and those with a family history of bipolar disorder or recurrent depression.11 For such patients, treatment should be continued for at least two to five years and, for some, indefinitely.

When to refer Referral to a psychiatrist should be considered when the patient has bipolar disorder, psychotic depression or active suicidal thoughts; when there is no response to one or two trials of treatment; or when there may be a need for ECT (ECT is effective for patients with psychotic depression or melancholic depression not responding to antidepressants). For patients requiring specialised psychological treatments, referral to either a psychiatrist or clinical psychologist may be necessary, the choice depending on factors such as individual therapist skill and the cost of therapy.

Antidepressants

 

 

Box 2:
Antidepressants marketed in Australia since 1990 - dosages and adverse effects

 

Box 3:
New antidepressants - important interactions

TCAs are still the most commonly prescribed antidepressants in many countries, including Australia. Although there has been concern that the newer antidepressants may be less effective than TCAs in severe or melancholic depression,27 the vast majority of depressed patients seen in the general practice setting have mild to moderate depression, for which the new antidepressants are as effective as the old. As there is consistent evidence of underprescription of TCAs and as the new medications are safer in overdose, the following order of antidepressant use in general practice is recommended:

First line: Selective serotonin reuptake inhibitors (SSRIs), venlafaxine, nefazodone, moclobemide or mianserin.

Second line: TCAs (desipramine or nortriptyline are preferred as they have fewer anticholinergic effects and are less sedating).

Third line: Irreversible monoamine oxidase inhibitors (MAOIs).

Details of the dosage, side effects and interactions of the more recently introduced antidepressants are provided in Box 2 and Box 3.

What should be done if the patient doesn't respond to a first-line antidepressant after four to six weeks?
At present there are few scientific data upon which to answer this question. While the occasional patient may benefit from switching within a particular class of medications (e.g., the SSRIs), there is more likelihood of response in changing to a different class (e.g., from an SSRI to a TCA or venlafaxine). An alternative approach is to augment the antidepressant with lithium, liothyronine sodium or pindolol (the latter for SSRIs only). (The pharmacological mechanisms of lithium and liothyronine augmentation are uncertain, but pindolol is thought to act by blocking the inhibitory 5-HT1a receptors on the serotonergic neuronal cell bodies -- an action that would enhance serotonergic transmission.)

What should be done if the patient cannot tolerate the adverse effects of an antidepressant?
First, it should be emphasised that many adverse effects of the antidepressants (e.g., nausea with SSRIs or sedation with TCAs) do settle within the first one or two weeks of treatment. If adverse effects are severe and persistent, it is best to switch classes of antidepressants, as classes such as SSRIs share adverse effect profiles. There is some evidence to suggest that patients may tolerate one drug in a class while failing to tolerate another (e.g., Brown et al.28 found that most patients who could not tolerate fluoxetine were able to tolerate sertraline).

Guidelines for changing antidepressants are provided in the Psychotropic drug guidelines.20 The major safety issues are (1) avoiding the serotonergic syndrome by allowing adequate time for drug clearance when switching between the irreversible MAOIs and other antidepressants, and (2) allowing adequate time for drug clearance when switching between SSRIs and other antidepressants, as SSRIs inhibit negative cytochrome P450 enzymes responsible for the metabolism of many of the antidepressants.

Withdrawal from antidepressants
Similar withdrawal syndromes have been described with the TCAs, SSRIs and venlafaxine, usually in patients who have been taking antidepressants for at least several months or at a high dose. The clinical syndrome is characterised by abdominal pain or discomfort, nausea, vomiting, diarrhoea, insomnia, rhinorrhoea, light-headedness and flu-like symptoms. Such withdrawal symptoms, while discomforting, are not dangerous and last only a maximum of two weeks.


Psychological treatments

 

Box 4:
Psychological therapies

A number of psychological treatments have been shown to be effective for depressed psychiatric outpatients (cognitive therapy and interpersonal therapy in particular; Box 4), but such treatments do not easily translate to general practice.

It is useful to discuss psychological treatments in terms of non-specific and specific forms:

Non-specific psychological treatments
These techniques were well described in the UK consensus statement on the management of depression in general practice.8 They may involve:

  • support, understanding, encouragement and explanation
  • meeting with other members of the family, or friends
  • advising environmental change
  • recommending self-help groups
  • contacting governmental and other agencies (e.g., housing departments) on behalf of the patient
  • helping the patient with problem solving
  • discussing chronic social difficulties with the patient.

Specific psychological treatments
Cognitive therapy and interpersonal therapy have been shown to be effective in depression, although most studies have been undertaken in the psychiatric setting. Some small studies, such as that of Scott et al.,29 have attempted (with some success) to tailor cognitive therapy to a form suitable for the general practitioner. There is also a trend in Australia for general practitioners to be trained in cognitive therapy skills. (One example of this is the Master in Psychological Medicine program for general practitioners offered through the University of New South Wales.)

The study of Mynors-Wallis et al. found that problem solving undertaken in either the patient's home or a local health centre was as effective as amitriptyline and more effective than placebo.17 Two of the three therapists in that study were general practitioners. Patients were given the rationale that emotional problems are caused by problems in the circumstances of their life, and that if problems were dealt with effectively symptoms would improve. Problems were then identified, listed, and dealt with one-by-one using problem solving methods. The first session took 60 minutes, with five subsequent sessions of 30 minutes.


Conclusion
  Much of the depression seen in the community can be dealt with adequately by general practitioners, who have a wide range of antidepressant medications and psychological treatments at their disposal to alleviate suffering from this severe and disabling disorder.

References
 
  1. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 study. JAMA 1995; 274: 1511-1517.
  2. Lloyd K, Jenkins R. The economics of depression in primary care. Department of Health Initiatives. Br J Psychiatry 1995; 166: 60-62.
  3. Simon G, Ormel J, Von Korff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152: 352-357.
  4. Sireling LI, Freeling P, Paykel ES, Rao BM. Depression in general practice: clinical features and comparison with outpatients. Br J Psychiatry 1985; 147: 119-126.
  5. Katon W, Lin E, Von Korff M, et al. The predictors of persistence of depression in primary care. J Affect Dis 1994; 31: 81-90.
  6. Dowrick C, Buchan I. Twelve month outcome of depression in general practice: does detection or disclosure make a difference? BMJ 1995; 311: 1274-1276.
  7. Donoghue JM, Tylee A. The treatment of depression: prescribing antidepressants in primary care in the UK. Br J Psychiatry 1996; 168: 164-168.
  8. Paykel ES, Priest RG. Recognition and management of depression in general practice: a consensus statement. BMJ 1992; 305: 1198-1202.
  9. Matthews K, Eagles JM, Matthews CA. The use of antidepressant drugs in general practice: a questionnaire survey. Eur J Clin Pharmacol 1993; 45: 205-210.
  10. Kerr MP. Antidepressant prescribing: a comparison between general practitioners and psychiatrists. Br J Gen Pract 1994; 44: 275-276.
  11. US Department of Health and Human Services. Agency for Health Care Policy and Research (AHCPR). Depression in primary care: Vol II. Treatment of major depression. AHCPR, 1993.
  12. Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Dis 1988; 14: 83-95.
  13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1968; 6: 278-296.
  14. Elkin I, Shea T, Watkins JT, et al. National Institute of Mental Health treatment of depression collaborative research program. Arch Gen Psychiatry 1989; 46: 971-982.
  15. Blackburn IM, Bishop S, Glen AIM, et al. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981; 139: 181-189.
  16. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry 1992; 49: 774-781.
  17. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995; 310: 441-445.
  18. Munoz RF, Hollon SD, McGrath E, et al. On the AHCPR depression in primary care guidelines: further considerations for practitioners. Am Psychologist 1994; 49: 42-61.
  19. Persons JB, Thase ME, Crits-Christoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry 1996; 53: 283-290.
  20. Psychotropic drug guidelines. 3rd ed. Melbourne: Victorian Drug Usage Advisory Committee, 1996.
  21. Depression in young people. A guide for general practitioners. Canberra: NHMRC, 1997.
  22. Depression in young people. A guide for mental health professionals. Canberra: NHMRC, 1997.
  23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994.
  24. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995; 10: 1500-1503.
  25. Glen AIM, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984; 14: 37-50.
  26. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-1099.
  27. Mitchell PB. The new antidepressants -- are they worth the cost? Aust Prescriber 1995; 18: 82-84.
  28. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56: 30-34.
  29. Scott JL, Tacchi MJ, Jones RH. Abbreviated cognitive therapy for depression: A pilot study in primary care. Behav Cogn Psychother 1994; 22: 57-64.
  30. American Psychiatric Association. Practice guideline for major depressive disorder in adults. In: American Psychiatric Association practice guidelines. Washington, DC: American Psychiatric Association, 1996: 79-134.

Authors' details
  Mood Disorders Unit, Prince Henry and Prince of Wales Hospitals, Sydney; School of Psychiatry, University of NSW, Sydney.
Philip B Mitchell, MD, FRANZCP, FRCPsych, Associate Professor.
Correspondence: Associate Professor P B Mitchell, School of Psychiatry, Prince Henry Hospital, Little Bay, NSW 2036.
E-mail: phil.mitchellATunsw.edu.au

On to Treatments that work in anxiety disorders . . .
To Contents list


Readers may print a single copy for personal use. No further reproduction or distribution of the articles should proceed without the permission of the publisher. For permission, contact the Australasian Medical Publishing Company
Journalists are welcome to write news stories based on what they read here, but should acknowledge their source as "an article published on the Internet by The Medical Journal of Australia <http://www.mja.com.au>".

<URL: http://www.mja.com.au/> © 1998 Medical Journal of Australia.